Global Neurodegenerative Disease Market - Segmented by Indication Type, Drug Type, Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4591891
  • Report
  • Region: Global
  • 112 pages
  • Mordor Intelligence
until Dec 31st 2018
1 of 5


  • Bayer Schering
  • Biogen Idec
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline Plc.
  • Merck Serono
  • Novartis International Ag
  • MORE
The neurodegenerative disease market is expected to witness a CAGR of 5.5% during the forecast period, 2018-2023. The market for neurodegenerative disease will experience robust growth, owing to the continuous developments that are made in the medical sector, which is both in the treatment and diagnosis of the neurological disorders.

Increasing Prevalence of Neurodegenerative Disorders

Along with increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. The Alzheimer's Association states that around 5.4 million people in the United States were been living with Alzheimer’s disease, as of 2016. This disease is the sixth leading cause of death in the United States and is more prevalent among people above 65 years of age (5.2 million out of the 5.4 million patients fall in this age bracket). The number is expected to increase during the forecast period, worsening the situation in the coming years. Thus, the prevalence of neurodegenerative disorders is on the rise, contributing to the growth of this market.

The other driving factors include the strong product pipeline for neurodegenerative diseases and new drug launches.

Patent Expiries During the Forecast Period

The neurodegenerative market is facing multiple patent expiries, which are likely to restrain the market globally. Some of the patents include Azilect’s patent expiring in May 2017, Comtan’s patent expiring in 2019, and Stalevo 50 in June 2020. Hence, it is anticipated that the market is going to face a downfall in the coming years. Rilutek, a drug that is used to treat Amyotrophic Lateral Sclerosis, will lose its patent protection in 2018, further reducing the growth of the market. These consecutive patent expiries will enable generics and players, offering low priced products, to enter the market, thus, causing a loss in the revenues for major key players, which is expected to impede the growth of the neurodegenerative market.

The other factors restraining the market include disease complexity and stringent regulations.

North America Dominates the Neurodegenerative Disease Market

With increasing aging population in the United States, a simultaneous increase in neurodegenerative diseases has been observed. Asia-Pacific has also been projected to have the fastest growth, owing to increasing population, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations, such as China, and India, in this region.

Key Developments in the Market
  • April 2017: Teva announced FDA approval of AUSTEDO tablets for the treatment of chorea associated with Huntington’s disease

Reasons to Purchase the Report
  • Current and future neurodegenerative disease market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report

This report can be customized to meet your requirements..
Note: Product cover images may vary from those shown
2 of 5


  • Bayer Schering
  • Biogen Idec
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline Plc.
  • Merck Serono
  • Novartis International Ag
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increased Prevalence of Neurological Disorders
6.1.2 Strong Product Pipeline for Neurodegenerative Diseases
6.1.3 New Drug Launches
6.2 Market Restraints
6.2.1 Patent Expiries During the Forecast Period
6.2.2 Disease Complexity
6.2.3 Stringent Regulations
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Indication Type
7.1.1 Parkinson’s Disease
7.1.2 Amyotrophic Lateral Sclerosis
7.1.3 Alzheimer’s Disease
7.1.4 Huntington Disease
7.1.5 Others
7.2 By Drug Type
7.2.1 N-methyl-D-aspartate receptor
7.2.2 Selective Serotonin Reuptake Inhibitor
7.2.3 Dopamine Inhibitors
7.2.4 Others
7.3 By Geography
7.3.1 North America United States Canada Mexico
7.3.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
7.3.3 Asia-Pacific China Japan India Australia & New Zealand South Korea Rest of Asia-Pacific
7.3.4 Middle East & Africa GCC South Africa Rest of the Middle East & Africa
7.3.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Bayer AG
9.2 Biogen Idec
9.3 Boehringer Ingelheim GmbH
9.4 GlaxoSmithKline plc
9.5 Merck Serono
9.6 Novartis International AG
9.7 Pfizer Inc.
9.8 Sanofi S.A.
9.9 Teva Pharmaceutical Industries Ltd
9.10 List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Novartis International Ag
  • Pfizer Inc.
  • Merck Serono
  • Biogen Idec
  • Teva Pharmaceutical Industries Ltd
  • Ucb
  • Bayer Schering
  • Boehringer Ingelheim Gmbh
  • Sanofi S.A.
  • Glaxosmithkline Plc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown